All patients	BuFlu	TreoFlu	p value
	n = 97	n = 67	n = 30
Age, median (min-max)	57 (19-73)	54 (19-70)	62 (26-73)	0,003
Sex, n (%)				0,107
Male	54 (55,7)	34 (50,7)	20 (66,7)
Female	43 (44,3)	33 (49,3)	10 (33,3)
Diagnoses, n (%)				0,595
AML	71 (73,2)	49 (73,1)	22 (73,3)
MDS	26 (26,8)	18 (26,9)	8 (26,7)
Disease status, n (%)				0,260
Complete remission	76 (78,4)	56 (83,6)	20 (66,7)
Partial remission	5 (5,2)	3 (4,5)	2 (6,7)
Progression/refractory	11 (11,3)	5 (7,5)	6 (20)
Never treated	5 (5,2)	3 (4,5)	2 (6,7)
Prior treatment lines, median (min-max)	1 (0-4)	1 (0-4)	1 (0-3)	0,102
HCT-CI score, n (%)				0,037
<3	47 (48,5)	37 (55,2)	10 (33,3)
≥3	50 (51,5)	30 (44,8)	20 (66,7)
Donor, n (%)				0,566
HLA-matched sibling	29 (29,9)	22 (32,8)	7 (23,3)
HLA-haploidentical sibling	19 (19,6)	11 (16,4)	8 (26,7)
HLA-matched unrelated	44 (45,4)	30 (44,8)	14 (46,7)
HLA-mismatched unrelated	5 (5,2)	4 (6)	1 (3,3)
Stem cell source, n (%)				0,064
Bone marrow	64 (66)	48 (71,6)	16 (53,3)
Peripheral blood	33 (34)	19 (28,4)	14 (46,7)
GvHD prophilaxis, n (%)				0,243
Calcineurin inhibitor + MMF/MTX	67 (69,1)	46 (68,7)	21 (70)
Cy post + FK + MMF	20 (20,6)	12 (17,9)	8 (26,7)
Cy post	10 (10,3)	9 (13,4)	1 (3,3)
ATG	28 (28,9)	18 (26,9)	10 (33,3)	0,338